See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Baseball
Natural Disasters
Social Media
Donald Trump
Trade War
Soccer
Tennis
Golf
US Politics
Stock Markets
Floods
Published • loading... • Updated

A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID

Summary by Nature
The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 has highlighted the vulnerability of a globally connected population to zoonotic viruses. The FDA-approved coronavirus antiviral Paxlovid targets the essential SARS-CoV-2 main protease, Mpro. Whilst effective in the acute phase of a COVID infection, Paxlovid cannot be used by all patients, can lead to viral recurrence, and does not protect against post-acute sequelae of COVID-19 (PASC), …

5 Articles

All
Left
Center
1
Right
NatureNature
Center

A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID

The COVID-19 pandemic caused by the coronavirus SARS-CoV-2 has highlighted the vulnerability of a globally connected population to zoonotic viruses. The FDA-approved coronavirus antiviral Paxlovid targets the essential SARS-CoV-2 main protease, Mpro. Whilst effective in the acute phase of a COVID infection, Paxlovid cannot be used by all patients, can lead to viral recurrence, and does not protect against post-acute sequelae of COVID-19 (PASC), …

·United Kingdom
Read Full Article
University of PlymouthUniversity of Plymouth

University manages UK’s first trial into potential for anti-viral drug to treat long COVID

University of Plymouth news: The University’s Peninsula Clinical Trials Unit is managing a groundbreaking project looking to find an effective treatment for the symptoms of long COVID

Read Full Article
fenews.co.ukfenews.co.uk

UK’s first long Covid anti-viral drug trials underway five years on

A ground-breaking research project looking to find a treatment for symptoms of long Covid is underway, as the nation marks five years since the start of the pandemic.The £1.25m trial, which is the first of its kind in the UK and led by the University of Derby, is exploring whether anti-viral medications can be used as an effective treatment option for patients diagnosed with long Covid.It is estimated that over two million people in the UK and m…

Read Full Article
NewswiseNewswise

New COVID-19 Drug Shows Greater Promise Against Resistant Viral Strains

A second-generation compound outperforms predecessor in the fight against coronavirus.

·Charlottesville, United States
Read Full Article
Knowridge Science ReportKnowridge Science Report

New COVID-19 pill shows strong protection against tougher virus strains

Scientists at Rutgers Health have developed a new COVID-19 drug that could be a powerful alternative to Paxlovid, the most commonly used oral treatment for the virus. This new drug, called Jun13296, may solve some of the biggest problems with current treatments—especially for people who take other medications. The research, led by Professor Jun Wang […] The post New COVID-19 pill shows strong protection against tougher virus strains appeared fir…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Knowridge Science Report broke the news in on Friday, April 4, 2025.
Sources are mostly out of (0)

Similar News Topics

Coronavirus

Coronavirus

Pandemic

Pandemic

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal